NCT04519567View on ClinicalTrials.gov

Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 31, 2020

Primary Completion Date

March 16, 2021

Study Completion Date

March 16, 2021

Conditions
Friedreich Ataxia
Interventions
BIOLOGICAL

CTI-1601

CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia

BIOLOGICAL

Placebo

Placebo Comparator

Trial Locations (1)

07724

Clinilabs Drug Development Corporation, Eatontown

Sponsors
All Listed Sponsors
collaborator

Veristat, Inc.

OTHER

collaborator

Metrum Research Group, LLC

UNKNOWN

lead

Larimar Therapeutics, Inc.

INDUSTRY